Study | Number of patients with CD4+ cell count <200 | Number of patients TST positive using ≥5 mm cutoff (%) | Number of patients TST positive using ≥10 mm cutoff (%) | Number of patients with CD4+ cell count 200-499 | Number of patients TST positive using ≥5 mm cutoff (%) | Number of patients TST positive using ≥10 mm cutoff (%) | Number of patients with CD4+ cell count ≥500 | Number of patients TST positive using ≥5 mm cutoff (%) | Number of patients TST positive using ≥10 mm cutoff (%) |
---|---|---|---|---|---|---|---|---|---|
Gupta et al. [33] | 50 | 8 (16.0) | 7 (14.0) | 326 | 71 (21.8) | 66 (20.2) | 307 | 65 (21.2) | 56 (18.2) |
Rangaka et al. [17] | 8 | 2 (25.0) | 2 (25.0) | 31 | 17 (54.8) | 16 (51.6) | 18 | 11 (61.1) | 10 (55.6) |
Karam et al. [18] | 145 | 11 (7.6) | 10 (6.9) | 85 | 25 (29.4) | 22 (25.9) | 43 | 23 (53.5) | 14 (32.6) |
Balcells et al. [26] | 13 | 1 (7.7) | 1 (7.7) | 73 | 4 (5.5) | 2 (2.7) | 23 | 7 (30.4) | 4 (17.4) |
Swaminathan et al. [34] | 150 | 64 (42.7) | 48 (32.0) | 313 | 138 (44.1) | 117 (37.4) | 160 | 67 (41.9) | 62 (38.8) |
Moura et al. [29] | 137 | 13 (9.5) | 13 (9.5) | 386 | 70 (18.1) | 61 (15.8) | 341 | 87 (25.5) | 78 (22.9) |
Nguyen et al. [40] | 75 | 31 (41.3) | 24 (32.0) | 206 | 116 (56.3) | 100 (48.5) | 88 | 57 (64.8) | 51 (58.0) |
Oni et al. [21] | 51 | 25 (49.0) | 21 (41.2) | 137 | 79 (57.7) | 73 (53.3) | 50 | 33 (66.0) | 30 (60.0) |
Samandari et al. [22] | 575 | 88 (15.3) | 74 (12.9) | 952 | 250 (26.3) | 212 (22.3) | 364 | 124 (34.1) | 93 (25.6) |